Artwork

Innhold levert av ReachMD. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av ReachMD eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Closing the Gaps in NSCLC

Del
 

Arkivert serier ("Inaktiv feed" status)

When? This feed was archived on August 02, 2022 08:10 (1+ y ago). Last successful fetch was on September 30, 2021 17:36 (2+ y ago)

Why? Inaktiv feed status. Våre servere kunne ikke hente en gyldig podcast feed for en vedvarende periode.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage series 2516546
Innhold levert av ReachMD. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av ReachMD eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking. In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC. This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only. Sponsored by
  continue reading

12 episoder

Artwork

Closing the Gaps in NSCLC

updated

iconDel
 

Arkivert serier ("Inaktiv feed" status)

When? This feed was archived on August 02, 2022 08:10 (1+ y ago). Last successful fetch was on September 30, 2021 17:36 (2+ y ago)

Why? Inaktiv feed status. Våre servere kunne ikke hente en gyldig podcast feed for en vedvarende periode.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage series 2516546
Innhold levert av ReachMD. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av ReachMD eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking. In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC. This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only. Sponsored by
  continue reading

12 episoder

Wszystkie odcinki

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett